Lipolysis defect in people with obesity who undergo metabolic surgery
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Lipolysis defect in people with obesity who undergo metabolic surgery. / Rydén, Mikael; Andersson, Daniel P.; Kotopouli, Maria I.; Stenberg, Erik; Näslund, Erik; Thorell, Anders; Sørensen, Thorkild I.A.; Arner, Peter.
In: Journal of Internal Medicine, Vol. 294, No. 4, 2022, p. 667-678.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Lipolysis defect in people with obesity who undergo metabolic surgery
AU - Rydén, Mikael
AU - Andersson, Daniel P.
AU - Kotopouli, Maria I.
AU - Stenberg, Erik
AU - Näslund, Erik
AU - Thorell, Anders
AU - Sørensen, Thorkild I.A.
AU - Arner, Peter
N1 - Publisher Copyright: © 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
PY - 2022
Y1 - 2022
N2 - Objective: Cross-sectional studies demonstrate that catecholamine stimulation of fat cell lipolysis is blunted in obesity. We investigated whether this defect persists after substantial weight loss has been induced by metabolic surgery, and whether it is related to the outcome. Design/Methods: Patients with obesity not able to successfully reduce body weight by conventional means (n = 126) were investigated before and 5 years after Roux-en-Y gastric bypass surgery (RYGB). They were compared with propensity-score matched subjects selected from a control group (n = 1017), and with the entire group after adjustment for age, sex, body mass index (BMI), fat cell volume and other clinical parameters. Catecholamine-stimulated lipolysis (glycerol release) was investigated in isolated fat cells using noradrenaline (natural hormone) or isoprenaline (synthetic beta-adrenoceptor agonist). Results: Following RYGB, BMI was reduced from 39.9 (37.5–43.5) (median and interquartile range) to 29.5 (26.7–31.9) kg/m2 (p < 0.0001). The post-RYGB patients had about 50% lower lipolysis rates compared with the matched and total series of controls (p < 0.0005). Nordrenaline activation of lipolysis at baseline was associated with the RYGB effect; those with high lipolysis activation (upper tertile) lost 30%–45% more in body weight, BMI or fat mass than those with low (bottom tertile) initial lipolysis activation (p < 0.0007). Conclusion: Patients with obesity requiring metabolic surgery have impaired ability of catecholamines to stimulate lipolysis, which remains despite long-term normalization of body weight by RYGB. Furthermore, preoperative variations in the ability of catecholamines to activate lipolysis may predict the long-term reduction in body weight and fat mass.
AB - Objective: Cross-sectional studies demonstrate that catecholamine stimulation of fat cell lipolysis is blunted in obesity. We investigated whether this defect persists after substantial weight loss has been induced by metabolic surgery, and whether it is related to the outcome. Design/Methods: Patients with obesity not able to successfully reduce body weight by conventional means (n = 126) were investigated before and 5 years after Roux-en-Y gastric bypass surgery (RYGB). They were compared with propensity-score matched subjects selected from a control group (n = 1017), and with the entire group after adjustment for age, sex, body mass index (BMI), fat cell volume and other clinical parameters. Catecholamine-stimulated lipolysis (glycerol release) was investigated in isolated fat cells using noradrenaline (natural hormone) or isoprenaline (synthetic beta-adrenoceptor agonist). Results: Following RYGB, BMI was reduced from 39.9 (37.5–43.5) (median and interquartile range) to 29.5 (26.7–31.9) kg/m2 (p < 0.0001). The post-RYGB patients had about 50% lower lipolysis rates compared with the matched and total series of controls (p < 0.0005). Nordrenaline activation of lipolysis at baseline was associated with the RYGB effect; those with high lipolysis activation (upper tertile) lost 30%–45% more in body weight, BMI or fat mass than those with low (bottom tertile) initial lipolysis activation (p < 0.0007). Conclusion: Patients with obesity requiring metabolic surgery have impaired ability of catecholamines to stimulate lipolysis, which remains despite long-term normalization of body weight by RYGB. Furthermore, preoperative variations in the ability of catecholamines to activate lipolysis may predict the long-term reduction in body weight and fat mass.
KW - adipocytes
KW - catecholamines
KW - glycerol
KW - Roux-en-Y gastric bypass
U2 - 10.1111/joim.13527
DO - 10.1111/joim.13527
M3 - Journal article
C2 - 35670497
AN - SCOPUS:85131322067
VL - 294
SP - 667
EP - 678
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
SN - 0955-7873
IS - 4
ER -
ID: 310378020